Recently, the mGlu5 receptor antagonist Basimglurant was administered as an adjunctive treatment to ongoing SSRI or SNRI treatment in a randomized, double-blind, placebo-controlled study, and an antidepressant effect was observed in patients with MDD, although the effect did not reach statistical significance when assessed using MADRS as a primary endpoint [ 73 ].
← all excerpts
Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants.
1
—
—